Algorae Pharmaceuticals (ASX:1AI) Ending Cash Position: A$1.13 Mil (As of Dec. 2025)


What is Algorae Pharmaceuticals Ending Cash Position?

Algorae Pharmaceuticals ASX:1AI Ending Cash Position is A$1.13 Mil as of Dec. 2025. The stock has 2 warning signs investors should review.

Algorae Pharmaceuticals's Ending Cash Position for the quarter that ended in Dec. 2025 was A$1.13 Mil.

Algorae Pharmaceuticals's quarterly Ending Cash Position increased from Dec. 2024 (A$0.31 Mil) to Jun. 2025 (A$0.47 Mil) and increased from Jun. 2025 (A$0.47 Mil) to Dec. 2025 (A$1.13 Mil).

Algorae Pharmaceuticals's annual Ending Cash Position declined from Jun. 2023 (A$4.11 Mil) to Jun. 2024 (A$0.81 Mil) and declined from Jun. 2024 (A$0.81 Mil) to Jun. 2025 (A$0.47 Mil).

Algorae Pharmaceuticals Ending Cash Position Related Terms

Algorae Pharmaceuticals Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Algorae Pharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Algorae Pharmaceuticals Ending Cash Position Chart

Algorae Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.57 4.24 4.11 0.81 0.47

Algorae Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.62 0.81 0.31 0.47 1.13

Algorae Pharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Algorae Pharmaceuticals's Ending Cash Position for the fiscal year that ended in Jun. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.808+-0.339
=0.47

Algorae Pharmaceuticals's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.468+0.665
=1.13

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of A$1.13 Mil mean?
Algorae Pharmaceuticals (ASX:1AI) has a Ending Cash Position of A$1.13 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Algorae Pharmaceuticals and its competitors.
Is Algorae Pharmaceuticals' Ending Cash Position too high?
Algorae Pharmaceuticals' current Ending Cash Position is A$1.13 Mil.
How does Algorae Pharmaceuticals' Ending Cash Position compare to VRTX and REGN?
Algorae Pharmaceuticals' Ending Cash Position of A$1.13 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Algorae Pharmaceuticals and its competitors. Algorae Pharmaceuticals's current Ending Cash Position is A$1.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Algorae Pharmaceuticals stock overvalued right now?
Algorae Pharmaceuticals (ASX:1AI) has a current Ending Cash Position of A$1.13 Mil. The current Ending Cash Position is A$1.13 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Algorae Pharmaceuticals (ASX:1AI), the current Ending Cash Position is A$1.13 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Algorae Pharmaceuticals Business Description

Other Exchanges LVCLF:USALHI0:Germany
Address 525 Collins Street, Level 23, Rialto South Tower, Melbourne, VIC, AUS, 3000
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for under met medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. The products of the company comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The company is conceptualized to be a potential treatment for dementia, including Alzheimer's disease, NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.